These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 10303401

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Evaluation of the maximum allowable cost program.
    Lee AJ, Hefner D, Dobson A, Hardy R.
    Health Care Financ Rev; 1983 Mar; 4(3):71-82. PubMed ID: 10309857
    [Abstract] [Full Text] [Related]

  • 3. MAC regulations: their predicted economic impact on pharmaceutical reimbursement.
    Gammill CG, Francis WR.
    Contemp Pharm Pract; 1981 Mar; 4(1):32-6. PubMed ID: 10298086
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pharmaceutical Reimbursement Board; suspension of maximum allowable cost limits on specific drug products--HCFA.
    Fed Regist; 1983 Sep 30; 48(191):44931. PubMed ID: 10262646
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM, Rebelein RP, Heaton PC, Ferrand Y, Guo JJ.
    J Ment Health Policy Econ; 2008 Mar 30; 11(1):33-47. PubMed ID: 18424875
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmaceutical Reimbursement Board; maximum allowable cost (MAC) limits and announcement of public hearing--HCFA. Proposed notice.
    Fed Regist; 1982 May 28; 47(104):23570-2. PubMed ID: 10261465
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Competitive health plans and alternative payment arrangements for physicians in the United States: public sector examples.
    Freund DA.
    Health Policy; 1987 Apr 28; 7(2):163-73. PubMed ID: 10301631
    [Abstract] [Full Text] [Related]

  • 16. Evidence and response to the impact of the Medicaid Drug Rebate Program (OBRA) on hospital pharmacy: a progress report from central Ohio.
    Taylor S, Kucukarslan S, Sherrin T.
    Hosp Pharm; 1991 Jul 28; 26(7):621, 624-5. PubMed ID: 10111796
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Washington State CARE Project: downstream cost changes associated with the provision of cognitive services by pharmacists.
    Smith DH, Fassett WE, Christensen DB.
    J Am Pharm Assoc (Wash); 1999 Jul 28; 39(5):650-7. PubMed ID: 10533346
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.